文献速递眼底病与葡萄膜炎

年龄相关性黄斑变性治疗比较试验中瘢痕的发生与演变

Development and Course of Scars in the Comparison of Age-Related Macular Degeneration Treatments Trials.
PubMed 文献 · Ophthalmology · 2018-02-14

基于CATT多中心前瞻性队列1061例受试者,评估5年内瘢痕形成的危险因素及纤维化瘢痕的变化。1、2、5年瘢痕累积比例分别为32%、46%、56%,经典脉络膜新生血管和大出血等形态特征与瘢痕形成相关。多数纤维化瘢痕及伴随的黄斑萎缩随时间扩大,视力下降。

要点

  • 1、2、5年瘢痕累积比例分别为32%、46%、56%,2年后新瘢痕形成速率下降。
  • 经典脉络膜新生血管(aHR 4.49)和大出血>1视盘面积(aHR 2.28)与瘢痕形成风险增加相关。
  • 多数纤维化瘢痕及伴随黄斑萎缩随时间扩大,68眼1年时纤维化瘢痕者1至5年平均视力额外下降13个字母。

核心结论

  • 多种形态特征包括经典脉络膜新生血管和大出血与瘢痕形成相关。
  • 新瘢痕形成速率在2年后下降。
  • 多数纤维化瘢痕及伴随的黄斑萎缩随时间扩大,导致视力下降。

研究设计与样本

  • 多中心、前瞻性队列研究,纳入CATT试验共1061例受试者。
  • 评估基线和1、2、5年彩色照相和荧光素血管造影图像。
  • 用Kaplan-Meier曲线估计瘢痕形成发生率,用Cox回归模型评估危险因素。

主要发现

  • 1、2、5年瘢痕累积比例分别为32%、46%、56%。
  • 基线危险因素(aHR,95%CI):经典CNV对比隐匿性为4.49(3.34-6.04);出血>1视盘面积(DA)对比无出血为2.28(1.49-3.47);视网膜厚度>212 μm对比<120 μm为2.58(1.69-3.94);视网膜下组织复合体厚度>275 μm对比≤75 μm为2.64(1.81-3.84);视网膜下液厚度>25 μm对比无液体为1.31(0.97-1.75);对侧眼视力20/20对比20/50或更差为1.72(1.25-2.36);无视网膜色素上皮隆起为1.71(1.21-2.41);视网膜下高反射物质为1.72(1.25-2.36)。
  • 68眼在1年时发生纤维化瘢痕,1至5年间视力平均额外下降13个字母。
  • 纤维化瘢痕平均面积在1、2、5年分别为1.2、1.2、1.9 DA;这些眼黄斑萎缩发生率分别为18%、24%、54%,平均面积分别为1.6、2.0、3.1 DA;5年时8眼萎缩取代纤维化瘢痕;瘢痕增长与萎缩增长无显著相关性;临床试验期与观察期两者增长率相似。

关键数值与推荐

  • 基线经典CNV对比隐匿性CNV的aHR为4.49(95%CI 3.34-6.04)。
  • 基线出血>1视盘面积对比无出血的aHR为2.28(95%CI 1.49-3.47)。
  • 基线视网膜厚度>212 μm对比<120 μm的aHR为2.58(95%CI 1.69-3.94)。
  • 基线视网膜下组织复合体厚度>275 μm对比≤75 μm的aHR为2.64(95%CI 1.81-3.84)。
  • 基线视网膜下液厚度>25 μm对比无液体的aHR为1.31(95%CI 0.97-1.75),未达统计学显著。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: To describe risk factors for scar formation and changes to fibrotic scar through 5 years in the Comparison of Age-related Macular Degeneration Treatments Trials (CATT). DESIGN: Multicenter, prospective cohort study. PARTICIPANTS: A total of 1061 subjects in CATT. METHODS: Color photographic and fluorescein angiographic images from baseline and 1, 2, and 5 years were evaluated. Incidence of scar formation was estimated with Kaplan-Meier curves. Risk factors were assessed with Cox regression models. MAIN OUTCOME MEASURES: Scar formation, fibrotic scar area, and macular atrophy associated with fibrotic scar ("atrophy"). RESULTS: Cumulative proportion of eyes with scar was 32%, 46%, and 56% at years 1, 2, and 5, respectively. Baseline factors associated with increased risk (adjusted hazards ratio [aHR] and 95% confidence interval [CI]) were classic choroidal neovascularization (CNV) (aHR, 4.49; 95% CI, 3.34-6.04) versus occult, hemorrhage >1 disc area (DA) (aHR, 2.28; 95% CI, 1.49-3.47) versus no hemorrhage, retinal thickness >212 μm (aHR, 2.58; 95% CI, 1.69-3.94) versus <120 μm, subretinal tissue complex thickness >275 μm (aHR, 2.64; 95% CI, 1.81-3.84) versus ≤75 μm, subretinal fluid thickness >25 μm (aHR, 1.31; 95% CI, 0.97-1.75) versus no fluid, visual acuity (VA) in fellow eye 20/20 (aHR, 1.72; 95% CI, 1.25-2.36) versus 20/50 or worse, retinal pigment epithelium elevation absence (aHR, 1.71; 95% CI, 1.21-2.41), and subretinal hyperreflective material (aHR, 1.72; 95% CI, 1.25-2.36). Among 68 eyes that developed fibrotic scar at year 1, VA decreased by a mean of additional 13 letters between years 1 and 5. Mean scar area was 1.2, 1.2, and 1.9 DA at 1, 2, and 5 years, respectively. Atrophy was present in 18%, 24%, and 54% of these eyes at years 1, 2, and 5, respectively; the mean areas were 1.6, 2.0, and 3.1 DA, respectively. Atrophy replaced fibrotic scar in 8 eyes at year 5. There was no significant correlation between scar growth and atrophy growth. The rate of growth for both was similar between the clinical trial and observation periods. CONCLUSIONS: Several morphologic features, including classic CNV and large hemorrhage, are associated with scar formation. Rate of new scar formation declined after 2 years. Most fibrotic scars and accompanying macular atrophy expanded over time, reducing VA.

来源:Ophthalmology,查看原文。版权归原作者所有。

引用

  1. Daniel E, Pan W, Ying GS, et al. Development and Course of Scars in the Comparison of Age-Related Macular Degeneration Treatments Trials. Ophthalmology. 2018. PMID: 29454660. doi:10.1016/j.ophtha.2018.01.004

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。